10-2010

Molecular Analysis Expands the Spectrum of Phenotypes Associated with GLI3 Mutations

Jennifer J. Johnston
National Human Genome Research Institute

Julie C. Sapp
National Human Genome Research Institute

Joyce T. Turner
National Human Genome Research Institute

David Tilstra MD
St. Cloud Hospital, CentraCare Health, tilstrad@centracare.com

Follow this and additional works at: https://digitalcommons.centracare.com/articles

Part of the Other Medical Specialties Commons

Molecular analysis expands the spectrum of phenotypes associated with *GLI3* mutations

Jennifer J. Johnston[1], **Julie C. Sapp**[1], **Joyce T. Turner**[1], **David Amor**[2], **Salim Aftimos**[3], **Kyrieckos A. Aleck**[4], **Maureen Bocian**[5], **Joann N. Bodurtha**[6], **Gerald F. Cox**[7], **Cynthia J. Curry**[8], **Ruth Day**[9], **Dian Donnai**[10], **Michael Field**[11], **Ikuma Fujiwara**[12], **Michael Gabbett**[13], **Moran Gal**[14], **John M. Graham Jr.**[15], **Peter Hedera**[16], **Raoul C.M. Hennekam**[17], **Joseph H. Hersh**[18], **Robert J. Hopkin**[19], **Hülya Kayserili**[20], **Alexa M.J. Kidd**[21], **Virginia Kimonis**[5], **Angela E. Lin**[22], **Sally Ann Lynch**[23], **Melissa Maisenbacher**[24], **Sahar Mansour**[25], **Julie McGaughran**[13], **Lakshmi Mehta**[26], **Helen Murphy**[10], **Margarita Raygada**[27], **Nathaniel H. Robin**[28], **Alan F. Rope**[29], **Kenneth N. Rosenbaum**[30], **G. Bradley Schaefer**[31], **Amy Shealy**[32], **Wendy Smith**[33], **Maria Soller**[34], **Annmarie Sommer**[35], **Heather J. Stalker**[24], **Bernhard Steiner**[36], **Mark J. Stephan**[37], **David Tilstra**[38], **Susan Tomkins**[39], **Pamela Trapane**[40], **Anne Chun-Hui Tsai**[41], **Margot I. Van Allen**[42], **Pradeep C. Vasudevan**[43], **Bernhard Zabel**[44], **Janice Zunich**[45], **Graeme C.M. Black**[10], and **Leslie G. Biesecker**[1]

[1] Genetic Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA [2] Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia [3] Northern Regional Genetic Service, Auckland City Hospital, Auckland, New Zealand [4] St Joseph's Hospital and Medical Center, Phoenix, Arizona, USA [5] Division of Genetics and Metabolism, Department of Pediatrics, University of California, Irvine Medical Center, Orange, California, USA [6] Department of Human and Molecular Genetics, Pediatrics, Obstetrics-Gynecology, Epidemiology and Community Health, Virginia Commonwealth University, Richmond, Virginia, USA [7] Division of Genetics, Children's Hospital Boston and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA; Clinical Research, Genzyme Corporation, Cambridge, Massachusetts, USA [8] Genetic Medicine Central California/University of California, San Francisco, California, USA [9] Cheshire and Merseyside Clinical Genetics Service, Liverpool, UK [10] Genetic Medicine, The University of Manchester, Manchester Academic Heath Science Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK [11] Clinical Genetics Department, Nepean Hospital, Penrith, New South Wales [12] Department of Pediatrics, Tohoku University School of Medicine, Tohoku University Hospital, Sendai, Miyagi, Japan [13] School of Medicine, The University of Queensland and Genetic Health Queensland, Royal Brisbane & Women's Hospital, Brisbane, Australia [14] Medical Genetic Institute, Shaare Zedek Medical Center, Jerusalem, Israel [15] Medical Genetics Institute, Cedars Sinai Medical Center, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA [16] Department of Neurology, Vanderbilt University, Nashville, Tennessee, USA [17] Department of Pediatrics, Academic Medical Center, University of Amsterdam, Meibergdreef, AZ Amsterdam [18] Department of Pediatrics, University of Louisville School of Medicine, Louisville, Kentucky, USA [19] Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA [20] Medical Genetics Department, Istanbul Medical Faculty, Istanbul University, Capa 34390 İstanbul, Turkey [21] Canterbury Health Laboratories, Christchurch, New Zealand [22] Massachusetts General

Corresponding author: Jennifer J Johnston, Building 49, Room 4C64, Bethesda, MD 20892-4472, Tel: 1-301-594-3981, Fax 1-301-402-2170, jjohnsto@mail.nih.gov.

Hospital, Boston, Massachusetts, USA [23] National Centre for Medical Genetics, Our Lady's Children's Hospital, Crumlin, Dublin 12, Republic of Ireland [24] Division of Genetics and Metabolism, Department of Pediatrics, University of Florida, Gainesville, Florida, USA [25] SW Thames Regional Genetics Service, St George's, University of London, London, UK [26] Division of Medical Genetics, Dept. of Genetics & Genomic Sciences, Mount Sinai School of Medicine, New York, New York, USA [27] Section on Clinical and Developmental Genomics, Program on Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA [28] Department of Genetics and Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA [29] University of Utah School of Medicine, Division of Medical Genetics, Salt Like City, Utah, USA [30] Department of Medical Genetics, Children's National Medical Center, Washington, DC, USA [31] Department of Genetics and Pediatrics, University of Arkansas for Medical Sciences, Section of Genetics and Metabolism, Department of Pediatrics, Arkansas Children's Hospital, Little Rock, Arkansas, USA [32] Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio USA [33] The Barbara Bush Children's Hospital Maine Medical Center, Portland, Maine, USA [34] University and Regional Laboratories Region Skåne, Division Clinical Genetics, Lund University Hospital, Lund, Sweden [35] Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio and Nationwide Children's Hospital, Columbus, Ohio, USA [36] Institute of Medical Genetics, University of Zurich, Schwerzenbach, Switzerland [37] Department of Pediatrics, Madigan Army Medical Center, Tacoma, Washington, USA [38] Department of Pediatrics, CentraCare Clinic, St Cloud, Minnesota USA [39] Clinical Genetics, University Hospitals Bristol, Bristol, UK [40] Department of Pediatrics, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA [41] Department of Pediatrics, University of Colorado Health Sciences Center, Denver, Colorado, USA [42] Department of Medical Genetics, University of British Columbia, Vancouver, B.C [43] Medical Genetics, University of Leicester, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Leicester, UK [44] Department of Pediatrics, University Hospital Freiburg, Freiburg, Germany [45] Genetics Center, Indiana University School of Medicine-Northwest, Gary, Indiana USA

Abstract

A range of phenotypes including Greig cephalopolysyndactyly and Pallister-Hall syndromes (GCPS, PHS) are caused by pathogenic mutation of the *GLI3* gene. To characterize the clinical variability of *GLI3* mutations, we present a subset of a cohort of 174 probands referred for *GLI3* analysis. Eighty-one probands with typical GCPS or PHS were previously reported, and we report the remaining ninety-three probands here. This includes nineteen probands (twelve mutations) who fulfilled clinical criteria for GCPS or PHS, forty-eight probands (sixteen mutations) with features of GCPS or PHS but who did not meet the clinical criteria (sub-GCPS and sub-PHS), twenty-one probands (six mutations) with features of PHS or GCPS and oral-facial-digital syndrome and five probands (one mutation) with non-syndromic polydactyly. These data support previously identified genotype-phenotype correlations and demonstrate a more variable degree of severity than previously recognized. The finding of *GLI3* mutations in patients with features of oral-facial-digital syndrome supports the observation that GLI3 interacts with cilia. We conclude that the phenotypic spectrum of *GLI3* mutations is broader than that encompassed by the clinical diagnostic criteria, but the phenotype-genotype correlation persists. Individuals with features of either GCPS or PHS should be screened for mutations in *GLI3* even if they do not fulfill clinical criteria.

Keywords

GLI3; Greig syndrome; Pallister-Hall syndrome; Oral-facial-digital syndrome

Introduction

Mutations in the zinc finger transcription factor encoding gene *GLI3* (MIM# 165240) on chromosome 7p14.1 cause Greig cephalopolysyndactyly syndrome (GCPS; MIM# 175700, (Vortkamp, et al., 1991)), Pallister-Hall syndrome (PHS, MIM# 146510 (Kang, et al., 1997)) and, less frequently, other phenotypes such as acrocallosal syndrome (MIM# 200990 (Elson, et al., 2002)) and non-syndromic polydactyly (MIM# 174700 (Radhakrishna, et al., 1999), 174200 (Radhakrishna, et al., 1997)). The GCPS and PHS phenotypes are clinically distinct and there is a robust genotype-phenotype correlation for truncating mutations in *GLI3* for these two phenotypes (Johnston, et al., 2005). Truncating mutations in the middle third of the gene generally cause PHS whereas large deletions or truncating mutations elsewhere in the gene (amino terminal-encoding or carboxy terminal-encoding thirds of the gene) cause GCPS. There are important biologic correlates for this genotype-phenotype correlation. The mutations that predict truncations in the amino-terminal third of the gene are predicted to be null mutations, caused by loss of the zinc finger DNA binding domain. In contrast, the truncations in the middle third of the protein are predicted to generate a constitutive repressor protein that skews the balance of activator and repressor forms of *GLI3*, which is a key downstream modulator of SHH signaling. The mutations that predict truncations in the carboxy-terminal third of the gene are predicted to cause the loss of a transactivation domain of *GLI3* (Shin, et al., 1999). To date, genotype-phenotype studies have been predominantly based on mutations found in patients with typical forms of GCPS and PHS and it therefore remains unclear whether there are variant phenotypes that are caused by mutations in *GLI3* and if so, whether the same correlations hold for these other phenotypes. To address these questions, we have continued to analyze a large cohort of 174 probands with a wide spectrum of phenotypic manifestations that include features of GCPS or PHS. Of these 174 probands, we present data on ninety-three patients not previously reported representing a wide range of phenotypes. We have analyzed *GLI3* in these patients to determine the frequency and type of mutations and assessed whether the mutation positions correlated with the phenotypes.

Methods

Patients

This study was reviewed and approved by the Institutional Review Board of the National Human Genome Research Institute. The overall *GLI3* project included 174 probands with features of PHS or GCPS. Ninety-three probands were the focus of this report and they were subdivided into the following groups according to inclusion criteria in Table 1. Eighty-one probands (174-93) have been reported previously (Galasso, et al., 2001;Johnston, et al., 2005;Killoran, et al., 2000;Kos, et al., 2008;Ng, et al., 2004;Turner, et al., 2003) and details on these probands are not included in this report.

Probands with features of GCPS or PHS insufficient to meet clinical criteria—
These probands had one or more features of GCPS or PHS but did not meet clinical criteria for either disorder. Detailed clinical data are reported for these latter fifty-three probands (plus nine relatives) who did not fulfill clinical criteria for either GCPS or PHS. Anomalies were defined according to the recently published standard terminology (Biesecker, et al., 2009; Hall, et al., 2009). This pool of fifty-three probands was subdivided into three groups based on phenotypic manifestations. The first group (twenty-eight probands and six affected family members, Tables 2–3) was designated as sub-GCPS and comprised patients with one or more features of GCPS, including preaxial polydactyly, cutaneous syndactyly, widely spaced eyes, or macrocephaly, but who did not meet the suggested clinical criteria for GCPS. The second group comprised patients who had one or more features of PHS, polydactyly, bifid epiglottis and/or hypothalamic hamartoma, but who did not meet the

published criteria. We refer to this group as sub-PHS patients (twenty probands and three affected family members, Tables 4–5). We placed individuals with isolated postaxial polydactyly (PAP-A) into a separate group which could overlap with PHS or GCPS as PAP-A is a manifestation of both GCPS and PHS (five probands).

Probands with features that overlapped with the oral-facial-digital syndromes—Key features of the oral-facial-digital syndromes (OFDS) include tongue and other oral hamartomas, multiple buccal-oral frenula, cleft lip and/or cleft palate, polydactyly, tibial hypoplasia, or cerebellar vermis hypoplasia (Gurrieri, et al., 2007). There are thirteen clinical types of OFDS but only OFDS type 1 has a known molecular etiology (Ferrante, et al., 2001). We delineated this group because there have been reports of patients with manifestations that overlapped PHS, oral-facial-digital syndrome, and other disorders (Muenke, et al., 1991). We identified twenty-one probands that had polydactyly and one or more features of an OFDS (Tables 6–7).

Probands with typical GCPS or PHS—Nineteen probands who fulfilled diagnostic criteria for GCPS (Johnston, et al., 2005) (seventeen probands) or PHS (Biesecker, et al., 1996) (two probands) were included in this report as they have not been reported previously. Detailed clinical data are reported for these nineteen probands (plus five relatives, Tables 8–11). The clinical diagnostic criteria for PHS require the presence of mesoaxial polydactyly and a hypothalamic hamartoma in the proband (Biesecker, et al., 1996). Suggested clinical criteria for GCPS include 1) preaxial polydactyly in at least one limb or broad great toes or thumbs, and 2) cutaneous syndactyly, macrocephaly, and wide spaced eyes (Biesecker, 2001). For this study we set GCPS eligibility criteria of pre-axial polydactyly and the presence of at least one additional feature (cutaneous syndactyly, macrocephaly, wide spaced eyes, postaxial polydactyly).

DNA Isolation, PCR and Sequencing

DNA was isolated from whole blood using the salting out method (Qiagen, Valencia, CA) following the manufacturer's instructions. PCR of *GLI3* exons and flanking intron sequences was performed using standard methods and primers as described (Johnston, et al., 2005). Sequencing of the *GLI3* coding exons was performed with v3.1 BigDye terminator cycle sequencing kit (Applied Biosystems, Foster City, CA) and either the ABI 377 (Applied Biosystems) or ABI 3100 (Applied Biosystems) per the manufacturer's protocol. Sequence data were compared with the published *GLI3* sequence (GenBank reference number NM_000168.5) using Sequencher 4.9 (Gene Codes Corp., Ann Arbor, MI). Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1. The entire coding region was sequenced for all probands except OFD2 due to insufficient DNA.

DHPLC Analysis

For some probands, screening of exons 3 through 12 and the last third of exon 15 was performed using dHPLC as described in (Johnston, et al., 2005).

Classification of Sequence Variants

We classified sequence variants as causative mutations if they were:

  a. a nonsense or frameshift variant or,

> **b.** a missense variant that predicted a non-conservative amino acid change and segregated with the phenotype in multiple family members or was *de novo* in a patient with a *GLI3*-related phenotype and unaffected parents

qPCR Analysis

qPCR was performed in a subset of individuals to identify deletions and duplications of *GLI3* exons. qPCR analysis of the *GLI3* coding exons was performed with the Platinum SYBR Green qPCR SuperMix UDG kit (Invitrogen) and the ABI PRISM 7000 (PE Applied Biosystems) as described in Johnston *et al.* 2005 (Table 3).

Array Hybridization

Zoom-in comparative genomic hybridization (CGH) for chromosome 7p14 was performed as described previously (Johnston, et al., 2007) in a subset of individuals to identify large deletions and duplications on chromosome 7 including *GLI3* (Tables 2, 3, 5, 6, 7, 8, 9 and 11).

FISH Analysis

FISH analysis was performed in a subset of individuals to identify large deletions on chromosome 7 in the vicinity of *GLI3*. FISH analysis was performed as described in Johnston *et al.* 2003 (Tables 3 and 7).

Results

The cohort delineated in this study included ninety-three probands and was drawn from a pool of 174 probands who were referred to our research protocol because they had one or more manifestations consistent with either (or both) GCPS or PHS. In addition, some of these probands were from multiplex families and clinical data on some of those affected family members are included in this cohort. These ninety-three probands were divided into several groups (see inclusion criteria, table 1) and each group is described in turn.

GLI3 mutations in probands with features of GCPS or PHS insufficient to meet clinical criteria

The first group included fifty-three probands with features that overlapped with GCPS or PHS, but these probands did not have sufficient features to warrant a clinical diagnosis of either disorder. Of these fifty-three probands, twenty-eight were categorized in the sub-GCPS group and eight of them had mutations. Of these eight mutations, five were frameshift or nonsense mutations, one was a splice mutation, one was a missense mutation, and one was a large genomic deletion. Four of the truncation or termination mutations were in the predicted domains (either 5′ of position 1998 or 3′ of 3481); c.4240C>T, which predicts p.Q1414X; c.4430_4431delCT, which predicts p.S1477X; c.4432G>T, which predicts p.E1478X; and c.4594_4596delTCCinsA, which predicts p.S1532TfsX2. The fifth was at the 3′ border of the PHS region; c.3474delG, which predicts p.I1160FfsX46. The splice site alteration, c.1497+1G>C, IVS10, has been identified previously (Kalff-Suske, et al., 1999). The missense alteration, c.2708C>T, which predicts p.S903L, was also identified in this study in a proband who fulfilled the clinical criteria for GCPS.

We noted that all five of the frameshift or nonsense mutations in the sub-GCPS group were located in the 3′ region of the gene. Overall, the mutation yield for patients with typical GCPS was thirty-nine of fifty-seven (68%), as compared to eight of twenty-eight (29%) for the sub-GCPS group ($p = 0.0006$, Fisher's exact test). The distribution of mutations for typical GCPS with frameshift or nonsense mutations is as follows; thirty-one were in the 5′ region, nine were in the PHS region, and fourteen were in the 3′ region (Fujioka, et al.,

2005; Furniss, et al., 2009; Johnston, et al., 2005). Interestingly, all five of the patients with sub-GCPS who have frameshift or nonsense mutations have those mutations in the 3′ region ($p = 0.0023$ Fisher's exact test). Of the twenty probands in the sub-PHS group, eight had mutations (40%). Of these eight mutations, all were nonsense or frameshift mutations and all but one of these mutations were in the previously defined PHS region (between cDNA positions 1998 and 3481). One proband had a c.3887_3894del mutation that predicts p.L1297SfsX4. As this mutation would be predicted to cause GCPS, some clinical details are provided here. The proband had bilateral mesoaxial polydactyly of the hand, isolated growth hormone deficiency without a hypothalamic hamartoma, and a bifid epiglottis. Her three affected family members have two to four limb postaxial polydactyly with a bifid epiglottis without a hypothalamic hamartoma. One family member had a broad forehead. The biologic mechanism of how this variant causes a sub-PHS phenotype requires further study.

Seven of the eight mutations in the sub-PHS group were novel. One mutation (c.2149C>T, p.Q717X) has been described previously in a patient with typical PHS (Johnston, et al., 2005). The overall mutation yield for the sub-PHS probands was eight of twenty (40%), which is significantly lower than for patients with typical PHS (twenty of twenty-two, 91%; $p = 0.0008$, Fisher's exact test).

One of five patients (20%) in the isolated PAP-A group was found to have a mutation in *GLI3*, c.874C>T, p.R292C. This mutation is upstream of the zinc finger in a conserved region of the protein.

GLI3 mutations in probands with features of oral-facial-digital syndromes

We identified twenty-one probands from our cohort who had one or more features of PHS or GCPS and in addition, one or more features of OFDS. Among these twenty-one probands we identified five frameshift or nonsense mutations that we concluded were pathologic and one large genomic deletion of 14.0 Mb. All five of the frameshift or nonsense mutations were similar in position within *GLI3* to other mutations that have been reported to cause PHS (Figure 1). Indeed, several of the probands in this group met the clinical criteria for PHS (OFD1, c.2077A>T, p.K693X; OFD2, c.2977C>T, p.Q993X, OFD3, c.3002delG, p.G1001AfsX2). Patient OFD4 with the c.3040G>T, p.E1014X mutation did not meet clinical criteria for PHS but he had oligodactyly, which we have observed in affected relatives of probands with typical PHS (unpublished observations). Similarly, patient OFD5 with the c.3371dupC, p.H1124PfsX5 mutation had postaxial polydactyly and a hypothalamic hamartoma. Although not sufficient for a clinical diagnosis of PHS, this combination of features has been observed in affected relatives of probands with PHS. Six of twenty-one patients with features that overlap an OFDS had a *GLI3* mutation for an overall yield of 29%. This yield of mutations is significantly below that for typical PHS (twenty of twenty-two, 91%, $p < 0.0001$, Fisher's exact test).

GLI3 mutations in probands with typical GCPS or PHS

The final group included patients with typical manifestations of GCPS or PHS. These patients were similar in their clinical manifestations to patients described previously (Johnston, et al., 2005). Among the seventeen probands with GCPS we identified eleven mutations. Of these eleven mutations, six were frameshift or nonsense mutations, two were missense mutations and three were large genomic deletions. Of the six frameshift or nonsense mutations, three were in the 5′ segment of *GLI3* (between the start codon and cDNA position 1998); c.1096C>T, which predicts p.R366X; c.1561_1576del, which predicts p.S521PfsX9, and c.1728C>A, which predicts p.Y576X. One nonsense mutation (c. 4072C>T, p.Q1358X) was in the 3′ segment of *GLI3* (between cDNA position 3481 and the

normal stop codon). Two nonsense or frameshift mutations were in the middle region of *GLI3* (between cDNA positions 1998 and 3481), which in most cases is associated with a phenotype of Pallister-Hall syndrome. Mutation (c.2374C>T; p.R792X) represents the eighth report of this variant associated with GCPS and this variant has been associated with nonsense-mediated mRNA decay (Furniss, et al., 2007). The second frameshift or nonsense mutation in the middle region of *GLI3* is c.2741delG, which predicts p.G914AfsX38. Two missense mutations were identified, c.1748G>T, p.C583F, and c.2708C>T, p.S903L. Of these eight mutations, six are novel. There were three probands in this group with deletions that included *GLI3* and ranged from 4.1 Mb to 12.2 Mb. All three of these deletions have novel breakpoints. These individuals were given a diagnosis of GCPS contiguous gene syndrome based on their molecular findings. This phenotype can include microcephaly or normocephaly, cognitive impairment, seizures, and other manifestations.

Of the two probands with PHS, one had a mutation in *GLI3*, c.2685C>G, p.Y895X. This mutation conforms to the previously described correlation that PHS mutations lie between cDNA positions 1998 and 3481 and is novel.

The overall yield of mutations was 65% for GCPS (eleven of seventeen) and 50% for PHS (one of two). We previously showed that among patients with typical GCPS, twenty-eight of forty patients had a *GLI3* mutation (70%) and nineteen of twenty probands with PHS had *GLI3* mutations (95%)(Johnston, et al., 2005). The results in the current study are similar for GCPS. Merging these data, the current estimates for GCPS would be thirty-nine of fifty-seven (68%) and for PHS would be twenty of twenty-two probands (91%).

Discussion

GLI3 mutations have been associated with several phenotypes including GCPS (Vortkamp, et al., 1991), PHS (Kang, et al., 1997) isolated polydactyly types A, A/B, and preaxial polydactyly type 4 (Radhakrishna, et al., 1999; Radhakrishna, et al., 1997), and a single case of acrocallosal syndrome (Elson, et al., 2002). By combining the data in this report with those of our prior work (Johnston, et al., 2005) we predict that when an individual manifests features sufficient for the clinical diagnostic criteria for PHS or GCPS, their chance of having a mutation in *GLI3* is high; 91% and 68%, respectively. The data presented here extend these observations into several distinct groups of patients.

In the early phases of gene discovery efforts, it is important to maximize the likelihood of locus homogeneity by setting strict clinical eligibility criteria. This was done successfully for PHS, and was likely done for GCPS as well. As noted above, nearly all patients who met the clinical criteria for PHS had a truncating mutation in the middle third of *GLI3*. In this study we hypothesized that a relaxation of the clinical criteria would identify additional patients with *GLI3* mutations. By relaxing the criteria to allow subjects with either mesoaxial polydactyly or hypothalamic hamartoma (but not requiring both), we show that a substantial proportion (50% or eight of sixteen) of patients have mutations in *GLI3*, a substantial and clinically useful yield that is slightly more than half the rate for patients who meet clinical criteria. When the criteria are relaxed even further to allow patients with syndromic postaxial polydactyly without mesoaxial polydactyly or hypothalamic hamartoma, no mutations were identified in four additional probands. Similar to the situation for PHS, the relaxation of the clinical criteria for GCPS allowed us to identify mutations in 29% of patients in the sub-GCPS category, again about half the yield for patients who meet the former criteria. We had a limited set of probands enrolled in the study who had non-syndromic polydactyly, which was mostly postaxial polydactyly. The yield in these patients was one of five or 20% but because this cohort is small, we believe that the implications of this finding are limited.

We also identified a cohort of patients who had one or more features of an oral-facial-digital syndrome. Other than OFDS type 1, there is no known molecular etiology for the many types that have been described (up to thirteen types have been proposed). We reasoned that some cases of OFDS could be caused by mutations in *GLI3* because: (1) there were a number of clinical reports of patients whose findings overlapped OFDS and PHS; (2) OFDS type 1 is a ciliopathy (Ferrante, et al., 2006); and (3) GLI3 requires ciliary function for proper processing (Haycraft, et al., 2005). We selected twenty-one cases from our cohort with one or more features of an OFDS. Some of the patients had sufficient features to warrant a diagnosis of PHS or GCPS as well, but some of the patients have been accepted as examples of an OFDS as evidenced by their publication in the literature (Fujiwara, et al., 1999; Stephan, et al., 1994). Among these twenty-one probands, we identified six cases with causative mutations in *GLI3*, establishing molecular evidence that mutations of this gene can cause phenotypes within the OFDS spectrum. Taken together, these data suggest that clinicians and molecular diagnostic laboratories should encourage a relaxation of clinical criteria for *GLI3* testing for patients with one or more features of GCPS or PHS. This would include patients with a feature of PHS or GCPS and one or more features of an OFDS. In this way additional patients will be diagnosed molecularly, which can be valuable for directing further clinical evaluations (endocrine and imaging studies), prognostic advice, molecular diagnostics in other family members, and family planning.

Beyond the clinical diagnostic utility, these data further the understanding of the biology of this gene and its pathway. The mutational spectra of typical GCPS and PHS are distinct; GCPS is caused by a wide range of mutations, but PHS is caused essentially only by truncating mutations. The data presented here, combined with published cases (Borg, et al., 2007; Fujioka, et al., 2005; Furniss, et al., 2009; Johnston, et al., 2005; Mendoza-Londono, et al., 2005; Roscioli, et al., 2005; Yilmaz, et al., 2008), describe 147 mutations in patients with typical GCPS or PHS. The mutation distribution in these two phenotypes is distinct. The GCPS mutations include large deletions/duplications (n=31) and translocations (n=5), and a variety of point mutations including missense (n=9), in frame deletions (n=1), splice (n=11), and frameshift or nonsense mutations (n=54). The distribution among patients with PHS is limited to one splice mutation and thirty-five frameshift or nonsense mutations. The difference in these mutation spectra is highly statistically significant (frameshift/nonsense vs. all other types; Fisher's exact test < 0.0001). We have previously shown that among the patients with truncating or frameshift mutations, the position of the mutations in *GLI3* robustly correlates with the phenotype; patients with PHS have mutations only in the middle portion of the gene (cDNA position 1998 to 3481), whereas patients with GCPS typically have mutations 5′ of position 1998 or 3′ of 3481. Again, the association between mutation position and phenotype is highly significant (3′ mutation vs. 5′ or middle segment, Fisher's exact test <0.0001).

The data presented here not only strengthen the known association among those with typical GCPS and PHS but also show the same mutation trend in atypical forms of the disorders. Among eight probands with sub-PHS, all eight mutations are frameshift or nonsense, whereas this is the case for slightly more than half, five of eight, of the sub-GCPS probands. Seven of eight of the PHS truncation or nonsense mutations lie in the middle third of the gene, whereas this is the case for none of five frameshift or nonsense mutations among patients with sub-GCPS. These data support the notion that the anomalies of GCPS and PHS are specific to their mutational mechanism, whether those anomalies are typical (PHS and GCPS) or atypical (sub-PHS and sub-GCPS).

There was no apparent correlation for the type or position of frameshift or nonsense mutations within the sub-PHS group that explained or predicted that these mutations caused an atypical phenotype as distinct from typical PHS, as all or nearly all were in the middle

third of the gene. However, we did find a correlation of mutations in sub-GCPS patients that distinguished them from GCPS. In probands with GCPS, the frameshift or nonsense mutations were distributed among the three segments of the gene; 5′ segment (n=31), middle segment (n=9), and 3′ segment (n=14). In contrast, five of five frameshift or nonsense mutations in probands with sub-GCPS were in the 3′ segment of the gene (3′ mutation vs. 5′ or middle segment, Fisher's exact test = 0.0023). These data suggest that the frameshift and nonsense mutations in the 3′ segment of the gene cause distinct biologic and phenotypic consequences from those in the other two segments of the gene.

The transition at nucleotide 1998 relates to the position of these mutations with respect to the zinc finger domain-encoding region and the normal proteolytic processing site of the *GLI3* protein (Kalff-Suske, et al., 1999). The transition at nucleotide 3481 may relate to the presence of the transactivation domain (Ruppert, et al., 1990; Shin, et al., 1999). There are known exceptions to these correlations. There is a recurrent c.2374C>T, p.R792X mutation, which lies within the PHS region of the gene, but in eight of eight families (including one proband in this report) is associated with a typical GCPS phenotype (Debeer, et al., 2003; Furniss, et al., 2009; Johnston, et al., 2005; Kalff-Suske, et al., 1999). A similar mutation, c. 2741delG, p.G914AfsX38, has been identified in a single family with a typical GCPS phenotype in this report. The proband in this case manifested postaxial polydactyly with macrocephaly and hypertelorism and had a family history of preaxial polydactyly. A third exception is a single family with PHS that has a splice mutation instead of a frameshift or nonsense mutation, although that mutation likely produces a truncated gene product (Johnston, et al., 2005). These data show that the clinical spectrum of phenotypes caused by mutations in *GLI3* is wider than previously appreciated. Further, they demonstrate that some mutant alleles of *GLI3* can cause malformations that are milder than the typical, clinically defined pleiotropic picture of these disorders, in that they do not demonstrate all of the features required for a clinical diagnosis. The previously reported association of mutation type and phenotype (PHS vs. GCPS) is strengthened by this report and it is extended into milder phenotypes as well. In addition, the distribution of frameshift and nonsense mutations in patients with sub-GCPS is distinct from that in those with typical GCPS, which suggests that these mutations are pathogenetically distinct. The data presented here should encourage molecular diagnostic laboratories to test a wider array of patients and the data should be useful to further understand the pathogenesis of these distinct pleiotropic developmental anomalies.

Acknowledgments

References

Biesecker, LG. GeneReviews at GeneTests: Medical genetics information resource (database online). Copyright, University of Washington; Seattle: 2001. Greig cephalopolysyndactyly syndrome; p. 1997-2004.

Biesecker LG, Aase JM, Clericuzio C, Gurrieri F, Temple IK, Toriello H. Elements of morphology: standard terminology for the hands and feet. Am J Med Genet A. 2009; 149A(1):93–127. [PubMed: 19125433]

Biesecker LG, Abbott M, Allen J, Clericuzio C, Feuillan P, Graham JM Jr, Hall J, Kang S, Olney AH, Lefton D, et al. Report from the workshop on Pallister-Hall syndrome and related phenotypes. Am J Med Genet. 1996; 65(1):76–81. [PubMed: 8914745]

Bonnemann CG, Drishnamoorthy KS, Johnston JJ, Lee MM, Fowler DJ, Bsiesecker LG, Holmes LB. Clinical and Molecular Heterogeneity of Syndromic Hypothalamic Hamartoma: Delineation of a Recognizable Mild Phenotype. Am J Med Genet. submitted.

Borg K, Nowakowska B, Obersztyn E, Cheung SW, Brycz-Witkowska J, Korniszewski L, Mazurczak T, Stankiewicz P, Bocian E. Complex balanced translocation t(1;5;7)(p32.1;q14.3;p21.3) and two microdeletions del(1)(p31.1p31.1) and del(7)(p14.1p14.1) in a patient with features of Greig cephalopolysyndactyly and mental retardation. Am J Med Genet A. 2007; 143A(22):2738–43. [PubMed: 17937435]

Debeer P, Peeters H, Driess S, De Smet L, Freese K, Matthijs G, Bornholdt D, Devriendt K, Grzeschik KH, Fryns JP, et al. Variable phenotype in Greig cephalopolysyndactyly syndrome: Clinical and radiological findings in 4 independent families and 3 sporadic cases with identified *GLI3* mutations. Am J Med Genet. 2003; 120A(1):49–58. [PubMed: 12794692]

Elson E, Perveen R, Donnai D, Wall S, Black GC. *De novo GLI3* mutation in acrocallosal syndrome: Broadening the phenotypic spectrum of *GLI3* defects and overlap with murine models. J Med Genet. 2002; 39(11):804–6. [PubMed: 12414818]

Ferrante MI, Giorgio G, Feather SA, Bulfone A, Wright V, Ghiani M, Selicorni A, Gammaro L, Scolari F, Woolf AS, et al. Identification of the gene for oral-facial-digital type I syndrome. Am J Hum Genet. 2001; 68(3):569–76. [PubMed: 11179005]

Ferrante MI, Zullo A, Barra A, Bimonte S, Messaddeq N, Studer M, Dolle P, Franco B. Oral-facial-digital type I protein is required for primary cilia formation and left-right axis specification. Nat Genet. 2006; 38(1):112–7. [PubMed: 16311594]

Fujioka H, Ariga T, Horiuchi K, Otsu M, Igawa H, Kawashima K, Yamamoto Y, Sugihara T, Sakiyama Y. Molecular analysis of non-syndromic preaxial polydactyly: preaxial polydactyly type-IV and preaxial polydactyly type-I. Clin Genet. 2005; 67(5):429–33. [PubMed: 15811011]

Fujiwara I, Kondo Y, Iinuma K. Oral-facial-digital syndrome with hypothalamic hamartoma, postaxial ray hypoplasia of the limbs, and vagino-cystic communication: a new variant? Am J Med Genet. 1999; 83(2):77–81. [PubMed: 10190476]

Furniss D, Critchley P, Giele H, Wilkie AO. Nonsense-mediated decay and the molecular pathogenesis of mutations in SALL1 and GLI3. Am J Med Genet A. 2007; 143A(24):3150–60. [PubMed: 18000979]

Furniss D, Kan SH, Taylor IB, Johnson D, Critchley PS, Giele HP, Wilkie AO. Genetic screening of 202 individuals with congenital limb malformations and requiring reconstructive surgery. J Med Genet. 2009; 46(11):730–5. [PubMed: 19429598]

Galasso C, Scire G, Fabbri F, Spadoni GL, Killoran CE, Biesecker LG, Boscherini B. Long-term treatment with growth hormone improves final height in a patient with Pallister-Hall syndrome. Am J Med Genet. 2001; 99(2):128–31. [PubMed: 11241471]

Gurrieri F, Franco B, Toriello H, Neri G. Oral-facial-digital syndromes: review and diagnostic guidelines. Am J Med Genet A. 2007; 143A(24):3314–23. [PubMed: 17963220]

Hall BD, Graham JM Jr, Cassidy SB, Opitz JM. Elements of morphology: standard terminology for the periorbital region. Am J Med Genet A. 2009; 149A(1):29–39. [PubMed: 19125427]

Haycraft CJ, Banizs B, Aydin-Son Y, Zhang Q, Michaud EJ, Yoder BK. Gli2 and Gli3 localize to cilia and require the intraflagellar transport protein polaris for processing and function. PLoS Genet. 2005; 1(4):e53. [PubMed: 16254602]

Johnston JJ, Olivos-Glander I, Killoran C, Elson E, Turner JT, Peters KF, Abbott MH, Aughton DJ, Aylsworth AS, Bamshad MJ, et al. Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes: robust phenotype prediction from the type and position of GLI3 mutations. Am J Hum Genet. 2005; 76(4):609–22. [PubMed: 15739154]

Johnston JJ, Walker RL, Davis S, Facio F, Turner JT, Bick DP, Daentl DL, Ellison JW, Meltzer PS, Biesecker LG. Zoom-in comparative genomic hybridisation arrays for the characterisation of variable breakpoint contiguous gene syndromes. J Med Genet. 2007; 44(1):e59. [PubMed: 17098889]

Kalff-Suske M, Wild A, Topp J, Wessling M, Jacobsen EM, Bornholdt D, Engel H, Heuer H, Aalfs CM, Ausems MG, et al. Point mutations throughout the *GLI3* gene cause Greig cephalopolysyndactyly syndrome. Hum Mol Genet. 1999; 8(9):1769–77. [PubMed: 10441342]

Kang S, Graham JM Jr, Olney AH, Biesecker LG. *GLI3* frameshift mutations cause autosomal dominant Pallister-Hall syndrome. Nat Genet. 1997; 15(3):266–8. [PubMed: 9054938]

Killoran CE, Abbott M, McKusick VA, Biesecker LG. Overlap of PIV syndrome, VACTERL and Pallister-Hall syndrome: Clinical and molecular analysis. Clin Genet. 2000; 58(1):28–30. [PubMed: 10945658]

Kos S, Roth K, Korinth D, Zeilinger G, Eich G. Hydrometrocolpos, postaxial polydactyly, and hypothalamic hamartoma in a patient with confirmed Pallister-Hall syndrome: a clinical overlap with McKusick-Kaufman syndrome. Pediatr Radiol. 2008; 38(8):902–6. [PubMed: 18478223]

Mendoza-Londono R, Kashork CD, Shaffer LG, Krance R, Plon SE. Acute lymphoblastic leukemia in a patient with Greig cephalopolysyndactyly and interstitial deletion of chromosome 7 del(7)(p11.2 p14) involving the GLI3 and ZNFN1A1 genes. Genes Chromosomes Cancer. 2005; 42(1):82–6. [PubMed: 15390181]

Muenke M, Ruchelli ED, Rorke LB, McDonald-McGinn DM, Orlow MK, Isaacs A, Craparo FJ, Dunn LK, Zackai EH. On lumping and splitting: a fetus with clinical findings of the oral-facial-digital syndrome type VI, the hydrolethalus syndrome, and the Pallister-Hall syndrome. Am J Med Genet. 1991; 41(4):548–56. [PubMed: 1776653]

Ng D, Johnston JJ, Turner JT, Boudreau EA, Wiggs EA, Theodore WH, Biesecker LG. Gonadal mosaicism in severe Pallister-Hall syndrome. Am J Med Genet. 2004; 124A(3):296–302. [PubMed: 14708104]

Radhakrishna U, Bornholdt D, Scott HS, Patel UC, Rossier C, Engel H, Bottani A, Chandal D, Blouin JL, Solanki JV, et al. The phenotypic spectrum of *GLI3* morphopathies includes autosomal dominant preaxial polydactyly type-IV and postaxial polydactyly type-A/B; No phenotype prediction from the position of *GLI3* mutations. Am J Hum Genet. 1999; 65(3):645–55. [PubMed: 10441570]

Radhakrishna U, Wild A, Grzeschik KH, Antonarakis SE. Mutation in *GLI3* in postaxial polydactyly type A. Nat Genet. 1997; 17(3):269–71. [PubMed: 9354785]

Roscioli T, Kennedy D, Cui J, Fonseca B, Watson GF, Pereira J, Xie YG, Mowat D. Pallister-Hall syndrome: unreported skeletal features of a GLI3 mutation. Am J Med Genet A. 2005; 136A(4): 390–4. [PubMed: 16007608]

Ruppert JM, Vogelstein B, Arheden K, Kinzler KW. GLI3 encodes a 190-kilodalton protein with multiple regions of GLI similarity. Mol Cell Biol. 1990; 10(10):5408–15. [PubMed: 2118997]

Shin SH, Kogerman P, Lindstrom E, Toftgard R, Biesecker LG. *GLI3* mutations in human disorders mimic Drosophila *cubitus interruptus* protein functions and localization. Proc Natl Acad Sci U S A. 1999; 96(6):2880–4. [PubMed: 10077605]

Stephan MJ, Brooks KL, Moore DC, Coll EJ, Goho C. Hypothalamic hamartoma in oral-facial-digital syndrome type VI (Varadi syndrome). Am J Med Genet. 1994; 51(2):131–6. [PubMed: 8092188]

Turner C, Killoran C, Thomas NS, Rosenberg M, Chuzhanova NA, Johnston J, Kemel Y, Cooper DN, Biesecker LG. Human genetic disease caused by *de novo* mitochondrial-nuclear DNA transfer. Hum Genet. 2003; 112(3):303–9. [PubMed: 12545275]

Vortkamp A, Gessler M, Grzeschik KH. *GLI3* zinc-finger gene interrupted by translocations in Greig syndrome families. Nature. 1991; 352(6335):539–40. [PubMed: 1650914]

Yilmaz Z, Gokdemir M, Derbent M, Sahin FI. Greig syndrome based on a de novo translocation. Pediatr Int. 2008; 50(2):248–50. [PubMed: 18353071]

Figure 1.
Diagram of the position within the gene of newly described nonsense and frameshift mutations in probands with sub-GCPS, sub-PHS and OFD-overlap. Some of the closely spaced mutations have been adjusted for increased visual clarity. Red bars denote the 5′ and 3′ limits of the PHS region at nucleotides 1998 and 3481 respectively. The colored bars on the protein show the conserved domains of GLI3 as defined elsewhere (Ruppert, et al., 1990).

Table 1

Inclusion criteria for patient groups

	Column A All required	Column B Minimum of one required	Column C Confirming features[1]
OFD-overlap	Polydactyly	Oral frenulae Oral hamartoma Clef lip/palate Cerebellar vermis hypoplasia Tibial hypoplasia	
PHS	Mesoaxial polydactyly Hypothalamic hamartoma		
GCPS	Preaxial polydactyly	Syndactyly Macrocephaly Hypertelorism Postaxial polydactyly	
Sub-PHS		Mesoaxial polydactyly Hypothalamic hamartoma Oligodactyly OR Postaxial polydactyly plus one feature from column C	Bifid epiglottis Imperforate anus Small nails Hypopituitarism Growth hormone deficiency Genital hypoplasia
Sub-GCPS		Preaxial polydactyly Broad thumbs or great toes Syndactyly Macrocephaly Hypertelorism OR Postaxial polydactyly plus one feature from column C	Hypoplasia of the corpus callosum

[1]Confirming features were used to place individuals with into sub-PHS or sub-GCPS groups when their only feature from column B was postaxial polydactyly.

Probands were evaluated sequentially for inclusion in the OFD-overlap group, then the PHS or GCPS groups and lastly the sub-PHS or sub-GCPS groups. Probands were placed into the first group where they fulfilled the inclusion criteria. Individuals who fulfilled the criteria for both sub-PHS and sub-GCPS were placed based upon the number of features they demonstrated for each group.

Table 2

Sub-GCPS patients with mutations

Individual	Mutation	Findings and Symptoms						MRI Findings	Additional Findings
		Mesoaxial Polydactyly	Postaxial Polydactyly	Preaxial Polydactyly	Cutaneous Syndactyly	Macrocephaly	Wide spaced eyes		
G1-1	c.1497+1G>C, IVS10		HB	HB3, FB3		+	+		
G1-2	c.1497+1G>C, IVS10		HB	HB3, FB3	FB		+		Autism
G1-3	c.1497+1G>C, IVS10		HB	HB3, FB3	2,3 toe		+		Speech delay
G2	c.2708C>T, p.S903L		-	HB3, FB					Hypospadias, nasal dermoid
G3-1	c.3474delG, p.I1160FfsX46		HB		HB				Wilms tumor
G3-2	c.3474delG, p.I1160FfsX46		HB						
G4-1	c.4240C>T, p.Q1414X		HR, FB		2,3 toe		+	Normal	Trigonocephalic skull shape, - frontal bossing, depressed nasal bridge, double hair whorl, absence of kidney, DD
G4-2	c.4240C>T, p.Q1414X		HR, FB		2,3 toe				High anterior hairline, prominent metopic sutures, broad nasal root and tip, hypospadias, DD
G5-1	c.4430_4431delCT, p.S1477X		HB, FB			+	+	Normal	
G5-2	c.4430_4431delCT, p.S1477X		HB, FB				+	Partial empty sella	Craniosynostosis of metopic sutures, bifid epiglottis, hypopituitarism, anosmia, Asperger's
G5-3	c.4430_4431delCT, p.S1477X		FB					Normal	
G6	c.4432G>T, p.E1478X	FL	HB	FB3	HR, FB	+		Hypoplasia of the CC	Fine motor delay
G7	c.4594_4596delTCCinsA, p.S1532TfsX2		HB	HB3, FB	HB, FB			Enlarged ventricles	Gingival overgrowth, estropia, high, narrow palate, hypotonia, DD
G8	Chr7:del41.7-44.9 Mb		HB	HB3, FB3	HL, FL	+	+	CCM	Strabismus, RSV pneumonitis/asthma, Umbilical hernia, SZ/DD

HB, hands bilateral; HR, hand right; HL, hand left; HB3, wide thumbs; FB, foot bilateral; FL, foot left; FB3, wider great toes; CC, corpus collosum; CCM, cerebral cavernous malformation; SZ, seizures; DD, developmental delay; +, presence of finding. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.

Table 3

Sub-GCPS patients without mutations

Individual	Deletion Analysis	Findings and Symptoms							
		Mesoaxial Polydactyly	Postaxial Polydactyly	Preaxial Polydactyly	Cutaneous Syndactyly	Macrocephaly	Wide spaced eyes	MRI Findings	Additional Findings
G9	Array	HB	FL		HB	microcephaly	+	Normal	Craniosynostosis, hernia, hypospadias, SZ, DD
G10			HB, FB			+		Hypoplasia of the CC, frontal polymicrogyria, cerebellar grey matter heterotopia	Umbilical hernia, transverse vaginal membrane, DD
G11			FR		HB	+	+		Dental cysts
G12	QPCR	Oligodactyly HR	HL, FR		HB, 2,3 toe	+	+	Enlarged ventricles	Coarse face, ears low set, with increased posterior angulation, hypodontia, GH deficient, DD
G13	QPCR		HB	HB3		+			DD
G14	QPCR		HB, FB			+		Normal	Short distal phalanges
G15	QPCR		HL, FB		FL	+	+	Mild colpocephaly	Skull asymmetry, high palate, dental crowding, long neck, pectus excavatum, prominent fetal pads, SZ, mild DD
G16	FISH		HB, FB				+	Prominent ventricles	Broad forehead, hydronephrosis, inguinal hernias, DD
G17	Array		HB		HB	microcephaly	+	Agenesis of CC	Frontal bossing, infantile spasms, extra rib, DD, hearing loss, constipation, contractures
G18	Array		HB	HB3	Broad hands with unusual creases	+	+	Hypoplasia of the CC	Prominent forehead, depressed nasal bridge, down slanted palpebral fissures, distinctive ears, mild 6th cranial nerve palsy, tracheomalacia with one narrow bronchus, shawl scrotum, elbow dimples, low tone
G19	QPCR			HL	2,3 toe			Hypoplasia of the CC	Bilateral club feet, VSD/ASD, iguinal hernia
G20	Array			FB				Agenesis of CC, cerebellar and brain stem hypoplasia, schizencephaly	High palate, 5th finger clinodactyly, left tibial bowing, deceased at 8 days
G21	QPCR			FB					
G22	Array			HB, FL					Short distal phalanges, absent finger nails, short humeri
G23	Array			HR				Increased CSF space on ultrasound	Hemivertebrae, 10 ribs bilaterally, mild plagiocephaly, depressed nasal bridge, frontal
G24	Array	Bifid second toe FL		FB3				Normal	Complex cardiac anatomy, bell shaped rib cage, hip dysplasia, small penis, retinal dysplasia, foveal hypoplasia, preauricular skin tag, diaphramatic hernia, supernumerary nipple, short metacarpals and metatarsals, cryptorchidism, scoliois
G25	Array				Complete 2,3 toe	+	+	Normal	Anteverted nares, short nose, hyperextensible joints, leg length discrepancy, DD
G26	Array				HL			Agenesis of CC, cerebellar and brainstem hypoplasia, midline cyst	Oral frenula, hydronephrosis, DD
G27	QPCR				+	+	+		

		Findings and Symptoms							
Individual	Deletion Analysis	Mesoaxial Polydactyly	Postaxial Polydactyly	Preaxial Polydactyly	Cutaneous Syndactyly	Macrocephaly	Wide spaced eyes	MRI Findings	Additional Findings
G28					HB, FB			Pontocerebellar hypoplasia, hypoplasia of the CC	Facial dysmorphism, redundant tongue tissue, ruffled gums, horseshoe kidney, deceased at 5 months, 2 affected siblings

HB, hands bilateral; HR, hand right; HL, hand left; HB3, wide thumbs; FB, foot bilateral; FR, foot right; FL, foot left; FB3, wide great toes; CC, corpus collosum; CSF, cerebral spinal fluid; GH, growth hormone; SZ, seizures; DD, developmental delay; VSD/ASD, ventricular/atrial septal defect; +, presence of finding.

Table 4

Sub-PHS patients with mutations

Individual	Mutation	Findings and Symptoms							
		Mesoaxial Polydactyly	Postaxial Polydactyly	Preaxial Polydactyly	Cutaneous Syndactyly	Craniofacial Features	Bifid Epiglottis	MRI Findings	Additional Findings
PH1	c.2149C>T, p.Q717X		HB		2,3 toe FB	Deep set eyes, small nose, diastema, small ears	+	HH with multicystic extension	Cloaca (many surgeries), unilateral renal agenesis, decreased renal function, thrombocytopenia, SZ, severe MR
PH2	c.2437C>T, p.Q813X				HB, FB		NA	HH	Small nails, PDA, ASD, tricuspid regurgitation, absent pituitary and adrenal glands, pulmonary hypertension, abnormal lung lobulation, imperforate anus, genital hypoplasia, deceased at 1 day
PH3	c.2466delG, p.M824X	oligodactyly HL; fusion of metacarpals		FL	HR: 2,3 toe FL; 2,3,4 FR		NA	HH	Small nails, deceased at 3 months
PH4	c.2542delG, p.D848TfsX12		HR			Macrocephaly, small teeth	+	HH	Visual problems, hearing problems, ectopic right kidney, GH deficiency, obesity, SZ, DD
PH5	c.2621_2624del, p.R874PfsX15		Bilateral				NA	HH	Small nails, pulmonary hypoplasia, absent pituitary gland, adrenal hypoplasia, thyroid hypoplasia, vaginal atresia, vesicovaginal fistula, hydrocolpos, bilateral renal hypoplasia, deceased antepartum at 41 weeks
PH6	c.3004delG, p.V1002X	oligodactyly HR					NA	HH	Osseous syndactyly of metacarpals and metatarsals, short stature, growth hormone deficient, laughing spells
PH7	c.3302dupA, p.N1101KfsX28		HB				+	HH	Small nails, hypoplastic toes, pointed teeth, midline frenula, laryngeal cleft, GH deficient, genital hypoplasia, neurosensory hearing loss, gelastic SZ
PH8-1	c.3887_3894del, p.L1297SfsX4	HB	FB				+	Enlarged cerebellar tonsils	Growth hormone deficient, 13:17 translocation
PH8-2	c.3887_3894del, p.L1297SfsX4		HB, FB				+	Normal	
PH8-3	c.3887_3894del, p.L1297SfsX4		HB				+		Thoracic scoliosis, nystagmus, DD
PH8-4	c.3887_3894del, p.L1297SfsX4		HB, FB			Broad forehead	+	Sphenoid sinus	Extra bone in right foot, chronic sinus problems, 13:17 translocation

HB, hands bilateral; HR, hand right; HL, hand left; FB, foot bilateral; FR, foot right; FL, foot left; HH, hypothalamic hamartoma; SZ, seizures; MR, mental retardation; PDA, patent ductus arteriosus; ASD, atrial septal defect; GH, growth hormone; DD, developmental delay; +, presence of finding. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.

NIH-PA Author Manuscript

Table 5

Sub-PHS patients without mutations

Individual	Deletion Analysis	Mesoaxial Polydactyly	Postaxial Polydactyly	Preaxial Polydactyly	Cutaneous Syndactyly	Craniofacial Features	Bifid Epiglottis	MRI Findings	Additional Findings
						Findings and Symptoms			
PH9			HB			Fine scalp hair	+	Disruption between hypothalamus and	Nuchal folds, hypotonia, panhypopituitarism, DD
PH10			HB			Microcephaly, pointed		Normal	Small nails, pituitary problem, microphallus, SZ, DD
PH11			HB			Depressed nasal	+	Normal	Small nails, panhypopituitarism, vaginal tag, hydronephrosis,
PH12			HB, FB		HB, FB	Large anterior	+	NA	Microphallus, unilateral undescended testes
PH13			HB		HB	Small mouth and	+	HH	Atrioventricular canal defect, deceased at 5 months
PH14	Array	HB, FB				Microcephaly, frontal bossing, mild dolichocephaly, high		Ventriculomegaly, periventricular leukomalacia	Slightly hypoplastic left 5th metacarpal, hypotonia, postnatal growth failure, pseudostrabismus, mild right estropia, bilateral accessory nipples, multiple bladder infection, urethral
PH15			HB			Plagiocephaly	short epiglottis	Possible HH, absent anterior pituitary	Laryngeal web, laryngeal cleft, ASD, mitral valve cleft, urethral reflux, hypopituitarism
PH16				HB3, FB3		Hypotelorism, left microphthamia, right anophthalm	NA	HH	Panhypopituitarism, choanal atresia, diaphragmatic hernia, severe DD
PH17							NA	HH	SZ, DD
PH18						Microcephaly, cleft lip	NA	HH	Microphallus, DD
PH19[1]						Oral frenulae	NA	HH	Hypoplastic fifth finger
PH20[1]						Oral frenulae	NA	HH	Hypoplastic middle phalanx of fifth digit, endocrine deficiency

HB, hands bilateral; HB3, wide thumbs; FB, foot bilateral; FB3, wide great toes; NA, not assessed; HH, hypothalamic hamartoma; DD, developmental delay; SZ, seizures; ASD, atrial septal defect; +, presence of finding.

[1](Bonnemann, submitted)

Table 6

OFD-overlap patients with mutations

		Findings and Symptoms										
Individual	Mutation	Mesoaxial Polydactyly	Postaxial Polydactyly	Preaxial Polydactyly	Oral frenula	Oral Hamartoma	Cleft Lip/ Palate	Cerebellar Vermis Hypoplasia	Tibial hypoplasia	Cutaneous Syndactyly	MRI Findings	Other Findings
OFD1[1]	c.2077A>T, p.K693X	HB	FR		+			+			HH	Esotropia, amblyopia, optic nerve hypoplasia, precocious puberty, supernumerary maxillary incisor, gelastic seizures, DD
OFD2	c.2977C>T, p.Q993X	HL	HL		+							Short palpebral fissures, short fingers, small nails, imperforate anus, ASD, deceased at 5 days
OFD3	c.3002delG, p.G1001AfsX2	HB					Palate	+			HH, Agenesis of the CC	Bilateral choanal atresia, small wide spaced eyes, small mouth, syngnathia, dysplastic kidney, short limbs, imperforate anus, short fingers, small nails, pregnancy terminated at 22 weeks
OFD4	c.3040G>T, p.E1014X	Oligodactyly HL	HR		+					HR	Hypothalamic mass	Absent left kidney, imperforate anus, deceased at 1 week
OFD5[2]	c.3370dupC, p.H1124PfsX5		HB, FB		+	+			R	HB, FB	HH, left cerebral atrophy	Short left ulna, small fibulae, hydrometrocol pos with a vagino-cystic fistula, precocious puberty, MR
OFD6	Chr7:del33.2-47.2 Mb			FB	+			+		+	Dilated ventricles, dural dermoid cyst	Macrocephaly, hypertelorism, bifid epiglottis, bilateral choanal hypoplasia, patent foramen ovale, horseshoe kidney, accessory spleen, bilateral undescended testes, kyphosis, deceased at 2.5 years

HB, hands bilateral; HR, hand right; HL, hand left; FB, foot bilateral; FR, foot right; FB3, wide great toes; HH, hypothalamic hamartoma; CC, corpus callosum; ASD, atrial septal defect; DD, developmental delay; +, presence of finding; +, presence of finding. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.

[1] (Stephan, et al., 1994),

[2] (Fujiwara, et al., 1999)

NIH-PA Author Manuscript

Table 7

OFD-overlap patients without mutations

Individual	Deletion Analysis	Findings and Symptoms									MRI Findings	Other Findings
		Mesoaxial Polydactyly	Postaxial Polydactyly	Preaxial Polydactyly	Oral frenula	Oral Hamartoma	Cleft Lip/Palate	Cerebellar Vermis Hypoplasia	Tibial hypoplasia	Cutaneous Syndactyly		
OFD7			HB, FB	HB, FB	Lip and Palate	+					Agenesis of CC, fused basal ganglia, abnormal cortical gyral pattern	Short limbs, club feet, AV canal, cystic pancreas, deceased
OFD8	FISH			HL	+					2,3 toe (−)		High anterior hairline, pyloric stenosis, underdeveloped ribs, microphallus, mild DD
OFD9	Array			FB			palate				Normal CT	Depressed nasal bridge, epilepsy, hydronephrosis, reflux, severe DD
OFD10	Array		HB	FB	+		lip, tongue	+		HB, FB		Mild hearing loss, wide spaced eyes, clefted epiglottis, DD
OFD12			FL		+							Mild hypospadias, SZ, DD
OFD12			HB, FB			+		+			Endocardial cushion defect, Dandy-Walker malformation	Small ears, bilateral polycystic kidney
OFD13			HB, FB				Lip/palate					Absent premaxilla and midline frenulum, VSD/ASD, absent pituitary, panhypopituitarism, DD
OFD14			HB		+	+		+			HH, Agenesis of CC	Wide spaced eyes, hypoplastic left heart, imperforate anus, deceased at 4 months of age
OFD15	FISH		HB	HB			palate				Normal	Wide spaced eyes, frontal bossing, depressed nasal bridge, micrognathia, retinal dysplasia, optic nerve hypoplasia, detached retina, severe hearing loss
OFD16	Array		HL, FB	HB, FB			Lip/palate	+		FB	HH	Absent fibulae, short ribs, short long bones, small jaw, pregnancy terminated at 20 weeks
OFD17		+		HB						HB	Agenesis of CC	Unilateral radius hypoplasia, bilateral tibia hypoplasia, gingiva overgrowth, cystic kidneys
OFD18			HB	FB	+	+	Lip/palate	+			Molar tooth sign, HH	Marked rhizomelic and mesomelic shortening with small hands and feet and brachydactyly, absent epiglottis, optic nerve colobomas with searching nystagmus and absent VERs, notched midline small jaw
OFD19			HL		+	+					Hamartoma	Macrocephaly, small finger nails, short 5th finger, second degree microtia, gelastic seizures, bifid tooth, absent tooth, supernumerary tooth
OFD20			HB, FB	HB, FB	+		Lip/palate				HH	Tethered tongue, vaginal atresia, DD, deceased
OFD21			+		+						HH, hypoplasia of cerebellum, dandy walker cyst with molar tooth sign	Macrocephaly, wide sutures, frontal bossing, broad depressed nasal bridge, deceased at 2 months

HB, hands bilateral; HL, hand left; FB, foot bilateral; FL, foot left; CC; corpus callosum; HH, hypothalamic hamartoma; NA, not assessed; DD, developmental delay; SZ, seizures; VSD/ASD, ventricular/atrial septal defect; +, presence of finding.

Table 8

GCPS patients with mutations

Individual	Mutation	Findings and Symptoms						MRI Findings	Additional Findings
		Mesoaxial Polydactyly	Postaxial Polydactyly	Preaxial Polydactyly	Cutaneous Syndactyly	Macrocephaly	Wide spaced eyes		
G29	c.1096C>T, p.R366X		HB	HB3, FB	HB, FB	+	+		Dental crowding, talipes equinovarus, undescended testis, right inguinal hernia
G30	c.1561_1576del, p.S521PfsX9			FB	FB	+	+	Hypoplasia of corpus callosum, calcified falx	Lipoma on forehead, delayed eruption of molars
G31	c.1728C>A, p.Y576X		HB	FB	FB	+	+		Craniosynostosis, epicanthal folds, depressed nasal bridge
G32	c.1748G>T, p.C583F		HB	FB	FB		+	Normal U/S	Umbilical hernia
G33-1	c.2374C>T, p.R792X		HB	FB	FB	+		Normal	SZ
G33-2	c.2374C>T, p.R792X		HB	FB				Normal	Broad nasal bridge
G34-1	c.2708C>T, p.S903L			FB	FB			Normal	Asthma
G34-2	c.2708C>T, p.S903L			HB, FB	FB	+	+	Agenesis of the CC, mild ventricular prominence	Dolichocephaly, sagittal craniosynostosis, bulbous nose, umbilical hernia with diastasis recti, DD
G34-3	c.2708C>T, p.S903L			FB	FB				High anterior hairline,
G35-1	c.2741delG, p.G914AfsX38		HB, FB		2,3 toe	+	+/atrial sep		Family history of preaxial polydactyly
G35-2	c.2741delG, p.G914AfsX38		HB, FB			+			
G36-1	c.4072C>T, p.Q1358X		HB, FB	FB					
G36-2	c.4072C>T, p.Q1358X		HB, FB	FB		+	+		Umbilical hernia, SZ, DD
G37	Chr7:del37.1-49.3 Mb		HB, FB	HB, FB	HB, FB	+		CCM, abnormal CC	Bilateral hydronephrosis, L-ureteral reflux, Course liver, Laryngomalacia, SZ/DD
G38	Chr7:del39.7-45.8 Mb			HB3, FB	2,3 toe	+	+	CCM, ventriculomegaly	Duane syndrome, VSD/ASD, SZ/DD
G39	Chr7:del41.0-45.1 Mb	FB	HB	FB, HB		+	+	Subdural effusion	Cryptorchidism, horizontal earlobe creases, antihelix pit, single transverse palmar crease of the left hand, SZ, DD

HB, hands bilateral; HR, hand right; FB, foot bilateral; CC, corpus collosum; CCM, cerebral cavernous malformation; SZ, seizures; DD, developmental delay; VSD/ASD, ventricular/atrial septal defect; +, presence of finding. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.

GCPS patients without mutations

Table 9

Individual	Deletion Analysis	Mesoaxial Polydactyly	Postaxial Polydactyly	Preaxial Polydactyly	Cutaneous Syndactyly	Macrocephaly	Wide spaced eyes	MRI Findings	Additional Findings
G41	Array			FL			+		
G42			HB	FB, soft tissue	HB			Agenesis of CC, brain cyst, brain stem hypoplasia	
G43	Array		HB	FB	FB				
G44	Array		HB	HR			+	Agenesis of CC	Small nose, prominent forehead, deformed ear, MR
G45	Array			FB			+	Porencephaly of left occipital and left temporal lobes, absence of septum pellucidum, hypoplastic optic nerves	Bilateral hernia, midline capillary vascular malformation, tetralogy of Fallot
G46	Array			HB3, FB	HB, FB				Trigonocephaly

HB, hands bilateral; HR, hand right; FB, foot bilateral; FL, foot left; HB3, wide thumbs; CC, corpus collosum; MR, mental retardation; +, presence of finding.

Table 10

PHS patients with mutations

		Findings and Symptoms							
Individual	Mutation	Mesoaxial Polydactyly	Postaxial Polydactyly	Preaxial Polydactyly	Cutaneous Syndactyly	Craniofacial Features	Bifid Epiglottis	MRI Findings	Additional Findings
PH21	c.2685C>G, p.Y895X	HB	HB		HB, FB			HH	Bilateral renal hypoplasia

HB, hands bilateral; FB, foot bilateral; HH, hypothalamic hamartoma. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.

Table 11

PHS patients without mutations

Individual	Deletion Analysis	Mesoaxial Polydactyly	Postaxial Polydactyly	Preaxial Polydactyly	Cutaneous Syndactyly	Craniofacial Features	Bifid Epiglottis	MRI Findings	Additional Findings
						Findings or Symptoms			
PH22	Array	HB					+	HH	Small nails, pointed teeth, genital hypoplasia, microglossia, MR

HB, hands bilateral; HH, hypothalamic hamartoma; MR, mental retardation; +, presence of finding.